论文部分内容阅读
目的:探讨分析吡格列酮合并二甲双胍治疗新诊断的2型糖尿病的临床疗效。方法:选取2011年12月至2014年12月来本院就诊的2型糖尿病患者130例,所有患者均符合2型糖尿病临床诊断标准,随机均分为合并组和单用组,每组患者各65例。合并组采用吡格列酮合并二甲双胍进行治疗,单用组采用单用二甲双胍进行治疗,对比两组患者的临床治疗效果。结果:两组患者治疗后空腹血糖水平、餐后2小时血糖水平及糖化血红蛋白情况比较,差异具有统计学意义(P<0.05)。两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论:吡格列酮合并二甲双胍治疗新诊断的2型糖尿病与单用二甲双胍比较,两者不良反应发生情况无明显差异且对人体伤害小,但合并用药能够很大程度的改善患者的血糖情况,因此吡格列酮合并二甲双胍治疗2型糖尿病较单用二甲双胍更值得在临床推广应用。
Objective: To investigate the clinical efficacy of pioglitazone combined with metformin in the newly diagnosed type 2 diabetes mellitus. Methods: A total of 130 type 2 diabetic patients who came to our hospital from December 2011 to December 2014 were enrolled in this study. All patients met the clinical diagnostic criteria of type 2 diabetes and were randomly divided into combined group and single group. 65 cases. The patients in the combined group were treated with pioglitazone combined with metformin. The patients in the combined group were treated with metformin alone. The clinical effects of the two groups were compared. Results: After treatment, fasting blood glucose level, postprandial blood glucose level at 2 hours and HbA1c were significantly different between the two groups (P <0.05). Adverse reactions between the two groups, the difference was not statistically significant (P> 0.05). CONCLUSION: Compared with metformin alone, the newly diagnosed type 2 diabetes with pioglitazone combined with metformin has no significant difference in side effects and less harm to human body. However, the combination therapy with pioglitazone and metformin can greatly improve the blood glucose level in patients with type 2 diabetes. Therefore, Metformin treatment of type 2 diabetes more than metformin more worthy of clinical application.